* Alliance sees threat of epidemic of chronic disease
* To invest tens of millions of dollars in research
* Focus is on "implementation science" projects
By Kate Kelland
LONDON (Reuters) - An alliance of the world's top public health researchers set out plans on Monday to invest tens of millions of dollars in heart and lung disease studies in a battle against a global epidemic of chronic disease.
The group of agencies, which together manage around 80 percent of global public health research funding, said the health impact and socio-economic costs of chronic non-communicable diseases (CNCDs) was "enormous and rising."
Experts estimate that unless action is stepped up, 388 million people worldwide will die prematurely in the next decade of chronic non-communicable diseases -- which include heart disease, stroke, some cancers, lung conditions, and type 2 diabetes.
"The epidemic of chronic disease in the world has accelerated. We urgently need to understand how to reverse the trend, not just in small trials, but in all the world communities," said Oxford University's David Matthews, executive director of the Global Alliance for Chronic Diseases (GACD).
Dr. Abdallah Daar of the McLaughlin-Rotman Center for Global Health in Toronto, GACD's chairman, said it expects to invest tens of millions of dollars in coordinated research programs over five years. He could not put a final figure on the projects, since grants have not yet been decided.
Around 11.5 million deaths a year are attributed to hypertension, or high blood pressure, tobacco and indoor air pollution from cooking stoves, the alliance said, making these three areas its first priorities.High blood pressure and tobacco use are often seen as health problems for richer nations, but the World Health Organization lists them as the top killers worldwide.Governments and wealthy donors have channeled billions of dollars in recent years into fighting infectious diseases such as malaria or the AIDS virus in the developing world, but chronic disease is now a growing threat there too.